From the Guidelines
The MinderaHealth Mind.Px test for psoriasis is indicated for patients 18 years of age and older. This genomic test is designed for adult patients with plaque psoriasis who are candidates for systemic therapy or biologic treatment. The test is not currently validated for use in pediatric populations under 18 years old. The age restriction exists because the test was developed and validated using data from adult populations, and the gene expression patterns that the test analyzes may differ in children and adolescents whose immune systems and inflammatory responses are still developing. Additionally, treatment algorithms and response patterns for psoriasis can vary between pediatric and adult populations, which affects the predictive value of such genomic testing 1. Some biologic agents, such as etanercept and ustekinumab, have been approved for use in pediatric patients with psoriasis, but at specific age ranges, for example, etanercept for patients over 6 years of age and ustekinumab for patients over 12 years of age 1. However, the Mind.Px test is not mentioned in these guidelines, and its use is not recommended for pediatric patients. Patients considering this test should consult with their dermatologist to determine if they meet all eligibility criteria beyond the age requirement, as other factors such as psoriasis type and severity also influence whether the Mind.Px test would be appropriate and beneficial for guiding treatment decisions. Key points to consider include:
- The test is designed for adult patients with plaque psoriasis
- The test is not validated for use in pediatric populations under 18 years old
- Treatment algorithms and response patterns for psoriasis can vary between pediatric and adult populations
- Biologic agents have been approved for use in pediatric patients with psoriasis, but at specific age ranges.
From the Research
Indication for MinderaHealth Mind.Px Test
- There is no information available in the provided studies regarding the MinderaHealth Mind.Px test for psoriasis, including the age at which it is indicated.
- The studies focus on various treatments for psoriasis, including biologic therapies, systemic agents, and topical medications 2, 3, 4, 5, 6.
- None of the studies mention the MinderaHealth Mind.Px test or its use in diagnosing or managing psoriasis.
- Therefore, there is no evidence to provide an answer to the question regarding the age at which the MinderaHealth Mind.Px test is indicated for psoriasis.